FR

Join us virtually for an opportunity to enhance your knowledge on the advancements in PsA and axSpA management. Together, we’ll explore the science behind these conditions and the exciting therapeutic breakthroughs.
Wednesday
December 31, 1969
7:00 pm - 7:00 pm EDT

FACULTY


ENGLISH BROADCAST SPEAKERS


Lihi Eder, MD, PhDAssociate Professor of Medicine and Research Director,
Division of Rheumatology,
University of Toronto
Scientist, Women’s College Research Institute
Toronto, Ontario

Nigil Haroon,
MD, PhD, DM, FRCPC, FRCP, MBADivision Head, Rheumatology,
UHN & Sinai Health
Senior Scientist, Krembil Research Institute
Toronto, Ontario

Kim A. Papp, MD, PhD, FRCPCPresident and Director of Research,
Probity Medical Research Waterloo, Ontario
Adjunct Professor of Medicine,
Department of Medicine,
University of Toronto
Toronto, Ontario


FRENCH BROADCAST SPEAKERS


Louis Bessette, MD, MSc, FRCPCAssociate Professor
Department of Medicine
Faculty of Medicine, Université Laval
Quebec, Quebec

Catherine Maari, MDAssociate Professor, Faculty of Medicine,
University of Montreal
Division of Dermatology,
Montreal University Hospital Center (CHUM)
and Saint-Justine Hospital
Montreal, Quebec

Nicolas Richard, MD, FRCPCAssistant Clinical Professor
Université de Montréal
Montreal, Quebec

LEARNING OBJECTIVES


Following this program, participants will be better able to:
  • Explain the role of IL-17A and IL-17F in the Pathogenesis of SpA
  • Discuss the Unmet Clinical Needs for the Treatment of PsA and axSpA
  • Review the Mechanism of Action, Efficacy and Safety data of bimekizumab, an IL-17A and IL-17F inhibitor, recently approved for the treatment of axSpA and PsA
  • Discuss the place of bimekizumab and other treatment options available in Canada for the treatment of PsA and axSpA

Please enter your information below to register for this event



I would like to attend the following webinar:
(Please note the timezones)

May 1, 2024




May 9, 2024








Please bring your own device to participate in the interactive portion of this program